Melanoma: all 3,073 studies

Page 8 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.

• Dendritic Cell Vaccination in Patients With Advanced MelanomaCompletedNCT03092453Phase 1Results posted
• Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging BiomarkerCompletedNCT03089606Phase 2Results posted
• Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized TrialActive, not recruitingNCT03075072Not applicableResults posted
• Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaCompletedNCT03070392Phase 2Results posted
• An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaCompletedNCT03068455Phase 3Results posted
• Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant MelanomaCompletedNCT03064763Phase 1Results posted
• Study in Subjects With Small Primary Choroidal MelanomaCompletedNCT03052127Phase 1/2Results posted
• Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney CancerTerminatedNCT03050060Phase 2Results posted
• Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic MelanomaCompletedNCT03047928Phase 1/2Results posted
• Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaCompletedNCT03033576Phase 2Results posted
• Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With MelanomaCompletedNCT03028948Not applicableResults posted
• A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) BlockadeCompletedNCT03003676Phase 1Results posted
• A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid TumorsCompletedNCT02983045Phase 1/2Results posted
• Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast CancerCompletedNCT02981303Phase 2Results posted
• A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With IpilimumabTerminatedNCT02978443Phase 2Results posted
• A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated MelanomaCompletedNCT02975700Not applicableResults posted
• Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain MetastasesTerminatedNCT02974803Phase 2Results posted
• Study of Combination of Ipilimumab and Nivolumab in Patients With MelanomaCompletedNCT02970981Phase 2Results posted
• A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaTerminatedNCT02967692Phase 3Results posted
• Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaActive, not recruitingNCT02965716Phase 2Results posted
• A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT02923349Phase 1/2Results posted
• A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced MelanomaCompletedNCT02908672Phase 3Results posted
• A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With MelanomaCompletedNCT02905266Phase 3Results posted
• IMCgp100-401 Rollover StudyTerminatedNCT02889861Phase 2Results posted
• Pembrolizumab in Advanced/Metastatic Acral Lentiginous MelanomaCompletedNCT02875132Phase 2Results posted
• Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III MelanomaActive, not recruitingNCT02858921Phase 2Results posted
• Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain MetastasesCompletedNCT02858869Phase 1Results posted
• Family Lifestyle Actions and Risk Education StudyCompletedNCT02846714Not applicableResults posted
• Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal MelanomaTerminatedNCT02831933Phase 2Results posted
• A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical StudiesCompletedNCT02829775Phase 2/3Results posted
• Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)CompletedNCT02821000Phase 1Results posted
• A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid TumorsCompletedNCT02819843Phase 2Results posted
• Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced MalignanciesCompletedNCT02807844Phase 1/2Results posted
• A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker StudyTerminatedNCT02796352Phase 2Results posted
• Imaging FDG Flare in MelanomaCompletedNCT02791594Results posted
• Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02771626Phase 1/2Results posted
• Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal MelanomaCompletedNCT02771340Phase 1Results posted
• A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)CompletedNCT02752074Phase 3Results posted
• Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV MelanomaTerminatedNCT02748564Phase 2Results posted
• Pembrolizumab and Ipilimumab After Prior Immunotherapy for MelanomaActive, not recruitingNCT02743819Phase 2Results posted
• Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal MelanomaTerminatedNCT02743611Phase 1/2Results posted
• Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive BiomarkerTerminatedNCT02740920Phase 2Results posted
• Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor TherapyCompletedNCT02731729Phase 2Results posted
• Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaTerminatedNCT02723006Phase 1Results posted
• Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung CancerCompletedNCT02718066Phase 1/2Results posted
• A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic MelanomaCompletedNCT02714218Phase 3Results posted
• Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid TumorsTerminatedNCT02709889Phase 1/2Results posted
• APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic MelanomaTerminatedNCT02706353Phase 1/2Results posted
• Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)CompletedNCT02681549Phase 2Results posted
• Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.CompletedNCT02678741Phase 1/2Results posted
• Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic MelanomaCompletedNCT02663232Results posted
• Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV MelanomaCompletedNCT02659540Phase 1Results posted
• Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV MelanomaActive, not recruitingNCT02656706Phase 2Results posted
• Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1Active, not recruitingNCT02650986Phase 1/2Results posted
• A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic MelanomaCompletedNCT02644967Phase 2Results posted
• A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersCompletedNCT02643303Phase 1/2Results posted
• Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced MelanomaCompletedNCT02599402Phase 3Results posted
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerCompletedNCT02595866Phase 1Results posted
• Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaTerminatedNCT02587650Phase 2Results posted
• Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous MelanomaCompletedNCT02581930Phase 2Results posted
• An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)CompletedNCT02574260Phase 2Results posted
• A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid TumorsCompletedNCT02573259Phase 1Results posted
• A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal MelanomaCompletedNCT02570308Phase 1/2Results posted
• Trial of Pembrolizumab and Radiotherapy in MelanomaTerminatedNCT02562625Phase 2Results posted
• Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)CompletedNCT02553642Phase 2Results posted
• A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. DacarbazineCompletedNCT02545075Phase 3Results posted
• A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT02521870Phase 1/2Results posted
• Neoadjuvant and Adjuvant Checkpoint BlockadeCompletedNCT02519322Phase 2Results posted
• Safety Study of a Helper Peptide Vaccine Plus PembrolizumabCompletedNCT02515227Phase 1/2Results posted
• A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node MappingCompletedNCT02509598Phase 2Results posted
• Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryActive, not recruitingNCT02506153Phase 3Results posted
• Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic MelanomaCompletedNCT02500576Phase 2Results posted
• Trial of pIL-12/MK-3475 in Metastatic MelanomaCompletedNCT02493361Phase 2Results posted
• Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerCompletedNCT02475213Phase 1Results posted
• Skin Care Behaviors Among Melanoma Survivors and Their FamiliesCompletedNCT02457065Not applicableResults posted
• A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid TumorsTerminatedNCT02452424Phase 1/2Results posted
• Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll MelanomaCompletedNCT02451488Phase 4Results posted
• Melanoma Perception and Health Literacy in People of ColorCompletedNCT02437305Not applicableResults posted
• Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833CompletedNCT02437227Phase 1Results posted
• Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)CompletedNCT02437136Phase 1/2Results posted
• A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced MelanomaCompletedNCT02434354Phase 1Results posted
• A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or ImmunotherapyCompletedNCT02431572Not applicableResults posted
• Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of MelanomaTerminatedNCT02425306Phase 1/2Results posted
• Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLCCompletedNCT02407171Phase 1/2Results posted
• Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced MelanomaCompletedNCT02403778Phase 2Results posted
• Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV MelanomaCompletedNCT02388906Phase 3Results posted
• A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With MelanomaTerminatedNCT02385669Phase 1/2Results posted
• Peginterferon and TIL Therapy for Metastatic MelanomaCompletedNCT02379195Phase 1/2Results posted
• A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic MelanomasTerminatedNCT02375984Phase 2Results posted
• Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected MelanomaCompletedNCT02366195Phase 2Results posted
• Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal MelanomaCompletedNCT02363283Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)Active, not recruitingNCT02362594Phase 3Results posted
• Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaCompletedNCT02360579Phase 2Results posted
• Vemurafenib and TIL Therapy for Metastatic MelanomaCompletedNCT02354690Phase 1/2Results posted
• Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver MetastasesTerminatedNCT02336763Not applicableResults posted
• Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck CancerCompletedNCT02331134Not applicableResults posted
• A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)CompletedNCT02327078Phase 1/2Results posted
• An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by ItselfCompletedNCT02320058Phase 2Results posted
• Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or TrametinibTerminatedNCT02314143Phase 2Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the BrainCompletedNCT02308020Phase 2Results posted

← Melanoma overview